BOT - Anything but charting, page-7395

I certainly don't get it. Kaken's figures show they're going to meet their $2.1bY income for Ecclock. If the US simply meets Japan's number of sales, as extrapolated below by Euroz Hartley's (17 Nov 2023), BOT are looking at a conservative revenue stream of $116m/year - if they just sell the same amount as Japan. Maybe that'll take 2 years to reach, so let's say BOT 'only' makes $50m in its first year. $50m revenue divided by 1.6b shares x 15PE = $0.47c. If the take-up is greater in the US because of BOT's sales strategy, and maybe account a little for 3 x times the population size in the US, then it's not hard to imagine easily hitting the +$100m/yr revenue and shares being worth north of $0.90c, based on nothing but Sofdra alone (no acne, no rosacea, no anti-microbial - all which have definite potential). And here we are at 19c!

Like you say, Sofdra's potential may finally be recognized when the subsequent "hard numbers" are released to the market. I'm amazed though that we might have to wait that long!